Interview with Thierry Teil, Managing Director, UCB Russia
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Address: Shabolovka str. 10Building 2, floor 3RUS – 119048 Moscow,Russia
Tel: +7 495 644 3322
Web: http://www.ucb.com/worldwide/Russia
UCB started operations in 1994, and after 2 partnering agreements, started local activities in 2005, further building its presence with Schwarz Pharma integration in 2007
UCB has two legal entities based in Moscow
– UCB Russia LLC
– UCB pharma Logistics LLC
Around 200 employees in 2011
UCB has representatives in the top 26 cities of Russia
In-market sales ~EURO 48 M in 2010
New legal entity: UCB Pharma Logistics
– Registred in 2010, Licenses granted, operational start in May. 2011
– Importation of UCB products in Russia and sales to distributors
– Partnership with a Russian distribution company FARMAT
Local manufacturing and packaging with Binnopharm
– Secondary packaging for a selected few products at the beginning
– Primary and secondary packaging planned
– Local manufacturing planned for later
– On-going finalization for this partnership on Local production, marketing and sales.
UCB Mature Products Continue to Improve Patients Outcome:
– Keppra :
Acknowledged worldwide as a landmark in the treatment of epilepsy, Keppra® is contributing to the wellbeing of thousands of Russian patients with epilepsy
-Xyzal and Zyrtec:
Bringing relief to patients with allergies, from allergic rhinitis to Chronic urticaria, in children and adults
-Isoket:
Leading nitrates in Russia for the treatment of angina pectoris with particularly helpful use in ambulances for Isoket ® spray
-Prostavasin:
Market leading treatment in conjunction to surgery for patients with Advanced Peripheral Obstructive Arterial disease as an alternative to amputation
All UCB Core Products in Russia: 2010-2011
UCB is becoming the Patient-Centric global biopharmaceutical leader
-Cimzia:
Fast response for predictable outcomes
-Vimpat:
When monotherapy is no longer enough
Launch in Russia in Sept 2010Already more than 300 severe epileptic patients treated
-Neupro:
24h continuous delivery by transdermal patch
Approval in Russia expected in July 2011 for Parkinson Disease
On-going launch following Phase 3 in Russia that has proven Cimzia’s benefit locallyNew treatment opportunity for patients with RA
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls and automated bots spread misinformation…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this company — from baby shampoo, to Tylenol when they…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of Commerce in Russia since 2001. Can you give a brief…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite…
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
See our Cookie Privacy Policy Here
